


CLAIMS

We claim:

1. A compound of Formula (I):



wherein:

- i) R_1 is aryl or heteroaryl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C_{1-5} acyl, C_{1-5} acyloxy, C_{2-6} alkenyl, C_{1-4} alkoxy, C_{1-6} alkyl, C_{1-5} alkylcarboxamide, C_{2-6} alkynyl, C_{1-4} alkylsulfonamide, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} alkylthio, C_{1-6} alkylureyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, carbo- C_{1-6} -alkoxy, carboxamide, carboxy, cyano, C_{3-7} cycloalkyl, C_{2-8} dialkylcarboxamide, C_{2-8} dialkylsulfonamide, halogen, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkylsulfinyl, C_{1-4} haloalkylsulfonyl, C_{1-4} haloalkylthio, hydroxyl, thiol, nitro, phenoxy and phenyl; and wherein C_{2-6} alkenyl, C_{1-6} alkyl and C_{2-6} alkynyl substituents may be optionally substituted with 1 to 5 substituents selected independently from the group consisting of C_{1-5} acyl, C_{1-5} acyloxy, C_{2-6} alkenyl, C_{1-4} alkoxy, C_{1-6} alkyl, C_{1-5} alkylcarboxamide, C_{2-6} alkynyl, C_{1-4} alkylsulfonamide, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} alkylthio, C_{1-6} alkylureyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, carbo- C_{1-6} -alkoxy, carboxamide, carboxy, cyano, C_{3-7} cycloalkyl, C_{2-8} dialkylcarboxamide, halogen, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkylsulfinyl, C_{1-4} haloalkylsulfonyl, C_{1-4} haloalkylthio, hydroxyl, thiol and nitro; or two adjacent substituents together with the ring carbons to which they are bonded form a C_{5-7} cycloalkyl optionally replaced with 1 to 2 oxygen atoms;
- ii) R_2 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-7} cycloalkyl;
- iii) R_3 is H, C_{2-6} alkenyl, C_{1-6} alkyl, C_{1-5} alkylcarboxamide, C_{2-6} alkynyl, C_{1-4} alkylsulfonamide, carbo- C_{1-6} -alkoxy, carboxamide, carboxy, cyano, C_{3-7} cycloalkyl, C_{2-8} dialkylcarboxamide, halogen, heteroaryl or phenyl; and

wherein C₂₋₆ alkenyl, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₁₋₄ alkylsulfonamide, C₃₋₇ cycloalkyl, heteroaryl or phenyl may be optionally substituted with 1 to 5 substituents selected independently from the group consisting of C₂₋₆ alkenyl, C₁₋₆ alkyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, C₂₋₆ alkynyl, C₂₋₈ dialkylamino, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, hydroxyl and thiol; and

iv) R₄ and R₅ are independently H, C₁₋₅ acyl, C₁₋₅ acyloxy, C₂₋₆ alkenyl, C₁₋₄ alkoxy, C₁₋₆ alkyl, C₁₋₅ alkylcarboxamide, C₂₋₆ alkynyl, C₁₋₄ alkylsulfonamide, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, C₁₋₆ alkylureyl, carbo-C₁₋₆-alkoxy, carboxamide, carboxy, cyano, C₃₋₇ cycloalkyl, C₂₋₈ dialkylcarboxamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfinyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thiol, 5 or 6 membered-heteroaryl, nitro, phenyl or NR₆R₇, and where the 5 or 6 membered-heteroaryl or phenyl is optionally substituted with a substituents selected from the group consisting of H, C₁₋₅ acyl, C₁₋₅ acyloxy, C₂₋₆ alkenyl, C₁₋₄ alkoxy, C₁₋₆ alkyl, C₁₋₅ alkylcarboxamide, C₂₋₆ alkynyl, C₁₋₄ alkylsulfonamide, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, C₁₋₆ alkylureyl, carbo-C₁₋₆-alkoxy, carboxamide, carboxy, cyano, C₃₋₇ cycloalkyl, C₂₋₈ dialkylcarboxamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfinyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thiol and nitro;

wherein:

R₆ and R₇ are independently selected from the group consisting of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, phenyl and benzyl group; wherein each said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, phenyl and benzyl group is optionally substituted with 1 to 5 substituents selected independently from the group consisting of H, C₁₋₅ acyl, C₂₋₆ alkenyl, C₁₋₄ alkoxy, C₁₋₆ alkyl, C₁₋₅ alkylcarboxamide, C₁₋₄ alkylthio, carbo-C₁₋₆-alkoxy, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, carboxamide, carboxy, cyano, C₃₋₇ cycloalkyl, C₂₋₈ dialkylcarboxamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfinyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thiol and nitro; or

R₆ and R₇ together with the nitrogen to which they are bonded form a 5, 6 or 7 membered cyclic structure which can be saturated or unsaturated and can contain up to four heteroatoms selected from O, NR₈ or S and said cyclic structure may be optionally substituted with 1 to 5 substituents selected independently from the group consisting of H, C₁₋₅ acyl, C₂₋₆ alkenyl, C₁₋₄ alkoxy, C₁₋₆ alkyl, C₁₋₅ alkylcarboxamide, C₁₋₄ alkylthio, carbo-C₁₋₆-alkoxy, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, carboxamide, carboxy, cyano, C₃₋₇ cycloalkyl, C₂₋₈ dialkylcarboxamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfinyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thiol and nitro;

R₈ is H or C₁₋₆ alkyl;

or

a pharmaceutically acceptable salt, hydrate or solvate thereof.


2. The compound according to claim 1 wherein R₁ is aryl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C₁₋₅ acyl, C₁₋₄ alkoxy, C₁₋₆ alkyl, C₁₋₅ alkylcarboxamide, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, carboxamide, carboxy, carbo-C₁₋₆-alkoxy, cyano, C₂₋₈ dialkylcarboxamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, hydroxyl, thiol, nitro and phenoxy; and where C₁₋₆ alkyl is optionally substituted with 1 to 3 substituents selected from the group consisting of C₁₋₄ alkoxy, C₁₋₅ alkylcarboxamide, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, hydroxyl and thiol.
3. The compound according to claim 2 wherein R₁ is aryl optionally substituted with 1 to 5 substituents selected independently from the group consisting of NO₂, F, Cl, Br, I, CF₃, CF₂CF₃, OCH₃, OCH₂CH₃, OCF₃, OCF₂CF₃, SCH₃, SCH₂CH₃, S(O)CH₃, S(O)CH₂CH₃, S(O)₂CH₃, S(O)₂CH₂CH₃, CO₂H, CN, COCH₃, COCH₂CH₃, CH₃, CH₂CH₃, NHCOCH₃, CH₂OH and OC₆H₅.
4. The compound according to claim 3 wherein R₁ is aryl optionally substituted with 1 to 3 substituents selected independently from the group consisting of NO₂, F, Cl, Br, I, CF₃, OCH₃, OCF₃, SCH₃, S(O)CH₃, S(O)₂CH₃, CN, COCH₃, CH₃, CH₂OH and OC₆H₅.

5. The compound according to claim 4 wherein R₁ is aryl optionally substituted with 1 to 3 substituents selected independently from the group consisting of NO₂, F, Cl, Br, I, CF₃, OCH₃, OCF₃, SCH₃, S(O)CH₃, S(O)₂CH₃, CN and CH₃.
6. The compound according to claim 5 wherein R₁ is aryl optionally substituted with 1 to 3 substituents selected independently from the group consisting of F, Cl, Br, I, CF₃, OCH₃ and OCF₃.
7. The compound according to claim 6 wherein the aryl group is phenyl substituted with 1 to 3 substituents selected independently from the group consisting of F, Cl and CF₃.
8. The compound according to claim 6 wherein the aryl group is 2-naphthyl substituted with 1 to 3 substituents selected independently from the group consisting of F, Cl and CF₃.
9. The compound according to claim 1 wherein R₁ is aryl and two adjacent substituents together with the ring carbons to which they are bonded form a C₅₋₇ cycloalkyl optionally replaced with 1 to 2 oxygen atoms.
10. The compound according to claim 9 wherein R₁ is a 3,4-methylenedioxyphenyl or 3,4-ethylenedioxyphenyl group.
11. The compound according to claim 1 wherein R₁ is heteroaryl and is optionally substituted with 1 to 5 substituents selected independently from the group consisting of C₁₋₅ acyl, C₁₋₄ alkoxy, C₁₋₆ alkyl, C₁₋₅ alkylcarboxamide, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, carboxamide, carboxy, carbo-C₁₋₆-alkoxy, cyano, C₂₋₈ dialkylcarboxamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, hydroxyl, thiol, nitro and phenoxy; and where C₁₋₆ alkyl is optionally substituted with 1 to 3 substituents selected from the group consisting of C₁₋₄ alkoxy, C₁₋₅ alkylcarboxamide, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, hydroxyl and thiol.
12. The compound according to claim 11 wherein R₁ is heteroaryl and is optionally substituted with 1 to 3 substituents selected independently from the group consisting

of C₁₋₄ alkoxy, C₁₋₆ alkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, carbo-C₁₋₆-alkoxy, carboxamide, carboxy, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, hydroxyl, thiol and nitro.

13. The compound according to claim 12 wherein the heteroaryl is selected from the group consisting of quinolinyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, quinazolinyl and pyrimidinyl.
14. The compound according to claim 13 wherein the heteroaryl is selected from the group consisting of benzoxazol-2-yl, quinolin-2-yl, quinolin-3-yl benzimidazol-2-yl, and benzothiazol-2-yl.
15. The compound according to any one of claims 1 to 15 wherein R₂ is C₁₋₆ alkyl.
16. The compound according to claim 15 wherein R₂ is CH₃, CH₂CH₃, CH(CH₃)₂ or CH₂CH₂CH₃.
17. The compound according to claim 16 wherein R₂ is CH₃.
18. The compound according to any one of claims 1 to 17 wherein R₃ is H, C₂₋₆ alkenyl, C₁₋₆ alkyl, C₂₋₆ alkynyl, carbo-C₁₋₆-alkoxy, carboxamide, carboxy, cyano, C₃₋₇ cycloalkyl, halogen, 5 membered-heteroaryl or phenyl; and where C₂₋₆ alkenyl, C₁₋₆ alkyl or phenyl group may be optionally substituted with 1 to 3 substituents selected independently from the group consisting of C₁₋₄ alkoxy, C₂₋₆ alkynyl, C₂₋₈ dialkylamino, halogen, C₁₋₄ haloalkoxy and hydroxyl.
19. The compound according to claim 18 wherein R₃ is H, Cl, Br, CO₂CH₃, CO₂CH₂CH₃, 2-hydroxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, vinyl, CH₃, CH₂CH₃, phenyl, 4-methoxyphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-trifluoromethoxyphenyl, thiophenyl, CO₂H, cyclopropyl, -CCH, -CH=CH-CCH or CN.
20. The compound according to claim 19 wherein R₃ is H, Cl or Br.

21. The compound according to any one of claims 1 to 20 wherein R_4 is H, halogen or NR_6R_7 .
22. The compound according to claim 21 wherein R_4 is H, F, $N(CH_3)_2$, or pyrrolidin-1-yl.
23. The compound according to any one of claims 1 to 22 wherein R_5 is H.
24. The compound according to any one of claims 1 to 20 having Formula (II):



wherein:

R_4 is H, C_{1-4} alkoxy, phenyl, halogen, 5 or 6 membered-heteroaryl, hydroxyl, thiol or NR_6R_7 , where the phenyl or heteroaryl group is optionally substituted with 1 to 5 substituents independently selected from the group consisting of C_{1-5} acyl, C_{1-4} alkoxy, C_{1-6} alkyl, C_{1-5} alkylcarboxamide, C_{1-4} alkylsulfonyl, C_{1-4} alkylthio, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, cyano, C_{2-8} dialkylcarboxamide, halogen, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, hydroxyl, thiol and nitro; and

wherein:


R_6 and R_7 are independently H, C_{1-6} alkyl, or

R_6 and R_7 together with the nitrogen to which they are bonded form a 5, 6 or 7 membered cyclic structure that may contain up to four heteroatoms selected from O, S or N- C_{1-4} alkyl; and

R_5 is H, C_{1-4} alkoxy, C_{1-6} alkyl, carboxamide, carboxy, cyano, halogen, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, hydroxyl, thiol or nitro.

25. The compound according to claim 24 wherein R_4 is H, Cl, F, dimethylamino, diethylamino, pyrrolidin-1-yl, morpholin-1-yl, 4-methylpiperazin-1-yl, 4-ethylpiperazin-1-yl, hydroxyl, thiol, OCH_3 or OCH_2CH_3 .
26. The compound according to claim 24 or 25 wherein R_5 is H or halogen.

27. The compound according to any one of claims 1 to 20 having Formula (IVa):



wherein:

R_4 is H, or C_{1-4} alkoxy; and

R_5 is H, C_{1-4} alkoxy, C_{1-6} alkyl, carboxamide, carboxy, cyano, halogen, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, hydroxyl, thiol or nitro.

28. The compound according to claim 27 wherein R_4 is OCH_3 .
29. The compound according to claim 28 wherein R_5 is H.
30. The compound according to claim 1 selected from the group consisting of:
 (4-Chloro-phenyl)-[3-(2-methyl-2H-pyrazol-3-yl)-phenyl]-amine;
 [3-(2-Methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethyl-phenyl)-amine;
 [3-(2-Methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethoxy-phenyl)-amine;
 [3-(2-Methyl-2H-pyrazol-3-yl)-phenyl]-(3-trifluoromethoxy-phenyl)-amine;
 [3-(2-Methyl-2H-pyrazol-3-yl)-phenyl]-(4-fluoro-phenyl)-amine;
 (4-Chloro-phenyl)-[4-methoxy-3-(2-methyl-2H-pyrazol-3-yl)-phenyl]-amine;
 (4-Chloro-phenyl)-[3-(2-isopropyl-2H-pyrazol-3-yl)-phenyl]-amine
 and
 (4-Fluoro-phenyl)-[3-(2-isopropyl-2H-pyrazol-3-yl)-phenyl]-amine.
31. The compound according to claim 1 selected from the group consisting of:
 [3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-chloro-phenyl)-amine;
 [3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethyl-phenyl)-amine;
 [3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethoxy-phenyl)-amine;

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-trifluoromethoxy-phenyl)-amine

and

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-fluoro-phenyl)-amine.

32. The compound according to claim 1 selected from the group consisting of:

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-methyl-4-chloro-phenyl)-amine;

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-chloro-4-trifluoromethyl-phenyl)-amine;

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,4-difluoro-phenyl)-amine;

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-chloro-phenyl)-amine;

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-methoxy-phenyl)-amine;

[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-(4-chloro-phenyl)-amine;

(4-Chloro-phenyl)-[3-(4-fluoro-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-amine;

and

(4-Chloro-phenyl)-[3-(4-fluoro-2-methyl-2H-pyrazol-3-yl)-phenyl]-amine.

33. The compound according to claim 1 selected from the group consisting of:

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2-nitro-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-chloro-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,5-bis-trifluoromethyl-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-methoxy-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,4-dimethoxy-phenyl)-amine;

1-{3-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenylamino]-phenyl}-ethanone;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,5-dichloro-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,5-dimethyl-phenyl)-amine;

N-{3-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenylamino]-phenyl}-acetamide;

{3-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenylamino]-phenyl}-methanol;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2-methyl-4-chlorophenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-phenoxy-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-trifluoromethyl-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-nitro-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2,3,4-trimethoxy-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-fluoro-4-methyl-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2,4-bis-trifluoromethyl-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-fluoro-4-methoxy-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2,3-difluoro-phenyl)-amine

and

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2,4-difluoro-phenyl)-amine.

34. The compound according to claim 1 selected from the group consisting of:

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-chloro-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-fluoro-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-methoxy-phenyl)-amine;

Benzo[1,3]dioxol-5-yl-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-trifluoromethoxy-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-bromo-phenyl)-amine;

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-methylsulfanyl-phenyl)-amine;

4-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenylamino]-benzonitrile;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethyl-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethoxy-
phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-methanesulfonyl-
phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-chloro-4-fluoro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,4-dichloro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-methyl-4-chloro-
phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,5-difluoro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-chloro-4-
trifluoromethyl-phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,4-difluoro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-methyl-4-fluoro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2-methyl-4-fluoro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-iodo-phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(2-methoxy-5-methyl-
phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-5-(*N,N*-dimethylamino)-phenyl]-(4-
chloro-phenyl)-amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-5-fluoro-phenyl]-(4-chloro-phenyl)-
amine;
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-5-pyrrolidin-1-yl-phenyl]-(4-chloro-
phenyl)-amine and
[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-(4-chloro-
phenyl)-amine.

35. The compound according to claim 1 selected from the group consisting of:
- [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-chloro-phenyl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-fluoro-phenyl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-trifluoromethoxy-phenyl)-amine;
 - 4-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenylamino]-benzonitrile;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethyl-phenyl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(4-trifluoromethoxy-phenyl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3-methyl-4-chloro-phenyl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(3,4-difluoro-phenyl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-(4-chloro-phenyl)-amine;
 - [3-(4-Bromo-2-isopropyl-2H-pyrazol-3-yl)-phenyl]-(4-fluoro-phenyl)-amine;
 - and
 - [3-(4-Bromo-2-isopropyl-2H-pyrazol-3-yl)-phenyl]-(4-chloro-phenyl)-amine.
36. The compound according to claim 1 selected from the group consisting of:
- [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-naphthalen-1-yl-amine and
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-naphthalen-2-yl-amine.
37. The compound according to claim 1 selected from the group consisting of:
- Benzoxazol-2-yl-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-quinolin-2-yl-amine;
 - (1H-Benzimidazol-2-yl)-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-amine;
 - Benzothiazol-2-yl-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(5-methoxy-benzothiazol-2-yl)-amine;
 - [3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-quinolin-3-yl-amine
 - and

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-(5-chloro-benzothiazol-2-yl)-amine.

38. A pharmaceutical composition comprising a compound according to any one of claims 1 to 37 and a pharmaceutically acceptable carrier.
39. A method for modulating the activity of a human 5HT_{2A} serotonin receptor comprising contacting the receptor with a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
40. A method for prophylaxis or treatment of reducing platelet aggregation in an individual comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
41. A method for prophylaxis or treatment of an indication selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, and atrial fibrillation in an individual comprising administering to said individual in need of said treatment or prophylaxis a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
42. A method for prophylaxis or treatment of reducing a risk of blood clot formation in an angioplasty or coronary bypass surgery individual, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
43. A method for prophylaxis or treatment of reducing risk of blood clot formation in an individual suffering from atrial fibrillation, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
44. A method for prophylaxis or treatment of asthma in an individual, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.

45. A method for the prophylaxis or treatment of a symptom of asthma in an individual, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
46. A method for the prophylaxis or treatment of agitation or a symptom thereof in an individual, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
47. The method according to claim 46 wherein said individual is a cognitively intact elderly individual.
48. A method for prophylaxis or treatment of agitation or a symptom thereof in an individual suffering from dementia, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
49. The method according to claim 48 wherein said dementia is due to a degenerative disease of the nervous system.
50. The method according to claim 49 wherein said dementia is Alzheimers disease, Lewy Body, Parkinson's disease, or Huntington's disease.
51. The method according to claim 48 wherein said dementia is due to diseases that affect blood vessels.
52. The method according to claim 48 wherein said dementia is due to stroke or multi-infarct dementia.
53. A method for prophylaxis or treatment of an individual suffering from at least one of the indications selected from the group consisting of behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute

schizophrenia, chronic schizophrenia and NOS schizophrenia comprising administering to said individual in need of such prophylaxis or treatment a dopamine D2 receptor antagonist and a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.

54. The method of claim 53 wherein said dopamine D2 receptor antagonist is haloperidol.
55. A method for prophylaxis or treatment of an individual with infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies comprising administering to said individual in need of such prophylaxis or treatment a dopamine D2 receptor antagonist and a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
56. The method according to claim 55 wherein said dopamine D2 receptor antagonist is haloperidol.
57. A method for prophylaxis or treatment of schizophrenia in an individual, comprising administering to said individual in need of such prophylaxis or treatment a dopamine D2 receptor antagonist and a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
58. The method of claim 57 wherein said dopamine D2 receptor antagonist is haloperidol.
59. A method for prophylaxis or treatment of alleviating negative symptoms of schizophrenia induced by the administration of haloperidol to an individual suffering from said schizophrenia, comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
60. The method according to any one of claims 54, 56, 58 and 59 wherein said haloperidol and said compound or pharmaceutical composition are administered in separate dosage forms.

61. The method according to any one of claims 54, 56, 58 and 59 wherein said haloperidol and said compound or pharmaceutical composition are administered in a single dosage form.
62. A method for prophylaxis or treatment of a sleep disorder in an individual comprising administering to said individual in need of such prophylaxis or treatment a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38.
63. A compound according to any one of claims 1 to 37 for use in a method of treatment of the human or animal body by therapy.
64. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of reducing platelet aggregation in the human or animal body by therapy.
65. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of an indication selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, and atrial fibrillation in the human or animal body by therapy.
66. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of reducing risk of blood clot formation in an angioplasty or coronary bypass surgery in the human or animal body by therapy.
67. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of reducing risk of blood clot formation in the human or animal body by therapy.
68. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of asthma in the human or animal body by therapy.
69. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of a symptom of asthma in the human or animal body by therapy.

70. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of agitation or a symptom thereof in the human or animal body by therapy.
71. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of at least one of the indications selected from the group consisting of behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia in the human or animal body by therapy.
72. A compound according to any one of claims 1 to 37 for use in a method for the prophylaxis or treatment of a sleep disorder in the human or animal body by therapy.
73. Use of a compound according to any one of claims 1 to 37 for production of a medicament for use in prophylaxis or treatment of a 5HT_{2A} mediated disorder.
74. The use according to claim 73 wherein the disorder is platelet aggregation.
75. The use according to claim 73 wherein the disorder is selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, and atrial fibrillation.
76. The use according to claim 73 wherein the disorder is a blood clot formation in an angioplasty or coronary bypass surgery individual.
77. The use according to claim 73 wherein the disorder is a blood clot formation in an individual suffering from atrial fibrillation.
78. The use according to claim 73 wherein the disorder is asthma.
79. The use according to claim 73 wherein the disorder is a symptom of asthma.

80. The use according to claim 73 wherein the disorder is agitation or a symptom thereof in an individual.
81. The use according to claim 80 wherein the individual is a cognitively intact elderly individual.
82. The use according to claim 73 wherein the disorder is agitation or a symptom thereof in an individual suffering from dementia.
83. The use according to claim 82 wherein the dementia is due to a degenerative disease of the nervous system.
84. The use according to claim 83 wherein the dementia is Alzheimers disease, Lewy Body, Parkinson's disease, or Huntington's disease.
85. The use according to claim 82 wherein the dementia is due to diseases that affect blood vessels.
86. The use according to claim 82 wherein the dementia is due to stroke or multi-infract dementia.
87. The use according to claim 73 further comprising a dopamine D2 receptor antagonist wherein the disorder is selected from the group consisting of a behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia.
88. The use according to claim 87 wherein said dopamine D2 receptor antagonist is haloperidol.
89. The use according to claim 73 further comprising a dopamine D2 receptor antagonist wherein the disorder is infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies.